RISPERIDONE DEPOT vs QUETIAPINE
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 666 participantsLow
Findings
What do systematic reviews say?
2,539 questions · 2,602 findings · 424 reviews · Headline outcomes only
No studies found 572 · 22%GRADE not reported 189 · 7.3%Very low 527 · 20.3%Low 685 · 26.3%Moderate 514 · 19.8%High 115 · 4.4%
RISPERIDONE DEPOT vs ARIPIPRAZOLE
Relapse · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
- RR 1.05 [0.83, 1.33]1 study · 349 participantsLow
RISPERIDONE DEPOT vs ARIPIPRAZOLE
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 349 participantsLow
RISPERIDONE DEPOT vs ARIPIPRAZOLE
Leaving the study early · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
- RR 0.83 [0.53, 1.3]2 studies · 723 participantsVery low
RISPERIDONE DEPOT vs OLANZAPINE
Relapse · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs OLANZAPINE
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 361 participantsLow
RISPERIDONE DEPOT vs OLANZAPINE
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
- RR 1.32 [1.1, 1.58]1 study · 618 participantsLow
RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Relapse · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
- RR 0.6 [0.45, 0.81]1 study · 749 participantsLow
RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Weight gain · patients with schizophrenia
1 finding from 1 review
- no estimate extracted3 studies · 2350 participantsLow
RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)
Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
- RR 1.79 [0.89, 3.61]3 studies · 2413 participantsLow
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Relapse · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 43 participantsLow
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
- RR 3.05 [1.12, 8.31]1 study · 62 participantsLow
RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS
Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Relapse · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
- RR 2.13 [0.84, 5.43]1 study · 63 participantsVery low
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
- RR 1.24 [0.98, 1.57]2 studies · 467 participantsModerate
Intervention not reported
Long‐term change in health status · Smokers who cannot or do not want to quit smoking
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Intervention not reported
Long term adverse effects or toxicity from observational studies
The review found no eligible studies for this question.
1 finding from 1 review
- Aquatic exercise for the treatment of knee and hip osteoarthritis 2016 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found